The Ministry of Health of Russia has broadened the catalog of cardiovascular diseases for which subsidized drugs are available. The new order was published on the internet portal for legal information and reports, with coverage noted by TASS. In particular, the expanded list now includes individuals who have suffered an acute cerebrovascular event, a heart attack, coronary heart disease accompanied by atrial fibrillation, and chronic heart failure characterized by a left ventricular ejection fraction of 40 percent as measured by echocardiography. This widening of eligibility aims to ensure that more patients receive essential medicines at reduced cost, improving access for those facing serious heart-related conditions and reducing the financial burden during treatment. Source attribution: TASS.
Beyond these conditions, discounted medicines are offered to patients who have undergone procedures such as coronary artery bypass grafting, coronary artery angioplasty with stent placement, and catheter ablation for cardiovascular diseases. The expansion reflects a policy focus on providing ongoing support to people who require complex interventions and long-term pharmacotherapy. It is designed to complement acute care with sustained treatment, lifestyle guidance, and regular medical follow-ups where appropriate. Source attribution: TASS.
Across the program, the drug list now contains more than 30 international non-proprietary names, underscoring a diverse range of medicines that address prevention, symptom control, and secondary prevention after events like a heart attack or stroke. This breadth helps clinicians tailor regimens to individual patient profiles and coexisting conditions, potentially improving adherence and outcomes over time. Source attribution: TASS.
Earlier, a physician from a regional health institution noted that self-medication can be harmless and beneficial for emergency situations or mild illnesses, but it should not substitute professional medical care, especially for serious ailments where misjudgment or delayed treatment could pose significant risks. The medical community continues to emphasize the importance of timely, evidence-based evaluation and the use of physician-guided therapy to maximize safety and effectiveness. Source attribution: TASS.
Past reports from Russian pharmacies also highlighted shortages of a widely used antidepressant, illustrating how drug supply dynamics can influence patient access to treatment. The situation underscores the need for ongoing monitoring of pharmaceutical supply chains, coordinated policy responses, and clear communication with the public about available therapeutic options. Source attribution: TASS.